Pharmaceuticals

Lucentis (Ranibizumab) Market 2026–2030: Forecasting Business Opportunities Ahead

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the lucentis (ranibizumab) market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Lucentis (Ranibizumab) Market by the end of 2030?

The Lucentis (ranibizumab) market has experienced substantial growth over recent years. Its value is anticipated to rise from $3.74 million in 2025 to $3.96 million in 2026, demonstrating a compound annual growth rate (CAGR) of 5.7%. The expansion observed in prior periods was primarily due to clinical achievements in macular degeneration, an increase in instances of diabetic retinopathy, the growing aging demographic, acceptance among ophthalmologists, and various regulatory approvals within the eye care industry.

The lucentis (ranibizumab) market is projected to experience robust expansion over the coming years, reaching a valuation of $4.87 million by 2030, driven by a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is primarily attributable to factors such as an increase in the prevalence of retinal diseases, improved access to eye care services, the expansion of biosimilar competition, a growing recognition of the importance of early diagnosis, and advancements in injection delivery technologies. Key trends anticipated for this period encompass the continued utilization of anti-VEGF therapies, an increase in the treatment of retinal vascular disorders, a developing preference for intravitreal injections, the proliferation of ophthalmology specialty clinics, and an enhanced emphasis on preserving vision.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19907&type=smp

What Drivers Are Shaping Future Opportunities In The Lucentis (Ranibizumab) Market?

An increase in eye-related conditions is anticipated to fuel the expansion of the Lucentis (ranibizumab) market moving forward. These disorders encompass a broad spectrum of conditions that impair ocular function. Factors contributing to their rising occurrence include aging populations, inherited predispositions, unhealthy lifestyle choices such as diet and smoking, and environmental influences like extended sun exposure or screen time. Lucentis functions by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for abnormal blood vessel development and leakage in the retina, which is a primary contributor to conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). For example, the National Eye Institute, a U.S. government body, projected in 2024 that 2.2 million Americans will be blind by 2030. Consequently, the growing incidence of eye-related disorders is a key impetus for the growth of the Lucentis (ranibizumab) market.

Which Segment Groups Are Influencing The Lucentis (Ranibizumab) Market?

The lucentis (ranibizumab) market covered in this report is segmented –

1) By Type: Single-use Prefilled Syringe, Single-use Glass Vial

2) By Application: Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Myopic Choroidal Neovascularization, Uveitis

3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

What Long-Term Trends Are Expected To Shape The Future Of The Lucentis (Ranibizumab) Market?

Leading companies in the Lucentis (ranibizumab) market are prioritizing the development of biosimilars, aiming to deliver more economical options compared to the original branded medication. Biosimilars are biological medical products that share a high degree of similarity with an already authorized reference biologic regarding their structure, effectiveness, and safety, presenting no clinically meaningful distinctions. As an illustration, during April 2024, the German biotechnology company Formycon AG, in collaboration with the Swiss biotechnology company Bioeq AG, launched their biosimilar iteration of Lucentis (ranibizumab), named FYB201, across Canada and Switzerland. Health Canada sanctioned the marketing of this biosimilar under the designation Ranopto, while Swiss Medic provided approval under the name Ranivisio. The introduction and subsequent market entry of FYB201 are intended to offer more accessible treatment choices for individuals affected by retinal diseases. Its mechanism involves blocking vascular endothelial growth factor A (VEGF-A), a protein known to stimulate abnormal blood vessel growth in the retina, which can lead to swelling, leakage, and impaired eyesight.

Who Are The Core Companies Influencing Trends In The Lucentis (Ranibizumab) Market?

Major companies operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/lucentis-ranibizumab-global-market-report

Which Regions Are Projected To Dominate The Lucentis (Ranibizumab) Market In The Coming Years?

North America was the largest region in the lucentis (ranibizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Lucentis (Ranibizumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19907&type=smp

Browse Through More Reports Similar to the Global Lucentis (Ranibizumab) Market 2026, By The Business Research Company

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795